NCT01509209COMPLETEDanonymous

Efficacy and Safety of Cossac L Tablet in Vasomotor Rhinitis Patients : A Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Trial

Sponsor

Source record

Hanmi Pharmaceutical Company Limited

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

Pseudoephedrine / Levocetirizine

Indication / condition

AI-normalized

Vasomotor Rhinitis

Intervention

Source record

Pseudoephedrine / Levocetirizine

Source & freshness

Source record

NCT ID

NCT01509209

Original source

ClinicalTrials.gov

Source last updated

May 23, 2013

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT01509209

Title

Efficacy and Safety of Cossac L Tablet in Vasomotor Rhinitis Patients : A Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Trial

Sponsor

Hanmi Pharmaceutical Company Limited

Status

COMPLETED

Phase

PHASE3

Condition raw

Vasomotor Rhinitis

Condition normalized

Vasomotor Rhinitis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Pseudoephedrine / Levocetirizine

Target normalized

Pseudoephedrine / Levocetirizine

Interventions

Pseudoephedrine / Levocetirizine

Public preview

Source record

The purpose of this study is to evaluate efficacy and safety of Cossac L tablet in the treatment of vasomotor rhinitis

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Efficacy and Safety of Cossac L Tablet in Vasomotor Rhinitis Patients : A Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Trial

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01509209

Status

COMPLETED

Phase

PHASE3

Sponsor

Hanmi Pharmaceutical Company Limited

Executive brief

Investment-Ready Snapshot

The purpose of this study is to evaluate efficacy and safety of Cossac L tablet in the treatment of vasomotor rhinitis

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedMay 23, 2013

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01509209

Indication

Vasomotor Rhinitis

Modality

small molecule

Target

Pseudoephedrine / Levocetirizine

Intervention

Pseudoephedrine / Levocetirizine

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.